Pharmaceuticals

Oncology Adjuvants Market to Reach $2.35 Billion by 2029, Growing at a CAGR of 8%

November 20, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Oncology Adjuvants Industry In 2025?

The oncology adjuvants market has experienced substantial growth in recent years. It is anticipated to expand from $1.59 billion in 2024 to $1.73 billion in 2025, representing a compound annual growth rate (CAGR) of 8.4%. This past growth can be attributed to several factors, including the increasing global incidence of cancer, a growing requirement for better preclinical predictability, the expanded utilization of patient-derived xenograft (PDX) models, a greater reliance on in vivo efficacy data, and an increased focus on early-stage immuno-oncology.

The oncology adjuvants market size is anticipated to undergo significant expansion in the upcoming years, projected to reach $2.35 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.0%. This growth during the forecast period is largely attributable to an increasing emphasis on human-relevant models, a rising demand for precision oncology, the proliferation of immuno-oncology treatments, a heightened need for high-throughput screening models, and expanding engagement with rare cancer models. Noteworthy trends in the forecast period encompass the integration of nanotechnology, adjuvants developed to enhance CAR-T cell therapies, progress in immuno-oncology adjuvants, and the utilization of artificial intelligence and machine learning.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27370&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Oncology Adjuvants Industry?

The future expansion of the oncology adjuvants market is anticipated to be driven by the escalating requirement for personalized medicine. This medical approach involves utilizing an individual’s genetic and lifestyle data to customize treatments and health interventions according to their unique requirements. Its increasing prevalence stems from progress in genetic and molecular profiling, facilitating therapies specifically adapted to a patient’s distinct biological characteristics, thereby enhancing efficacy and minimizing side effects. Oncology adjuvants support personalized medicine by enabling the tailoring of supplementary cancer treatments, considering a patient’s specific genetic profile and tumor attributes. This ensures effective targeting of remaining cancer cells and reduces unwanted side effects. An example illustrates this trend: in February 2023, the Personalized Medicine Coalition, a US-based professional membership organization, reported that in 2022, 12 new personalized medicines received approval, accounting for roughly 34% of all recently approved therapies, which signifies a notable rise compared to prior years. Consequently, the expanding need for personalized medicine is fueling the growth within the oncology adjuvants market.

How Is The Oncology Adjuvants Market Classified Into Different Segments?

The oncology adjuvants market covered in this report is segmented

1) By Type Of Adjuvant: Chemotherapy Adjuvants, Radiation Adjuvants, Immunotherapy Adjuvants, Hormonal Adjuvants, Targeted Therapy Adjuvants

2) By Administration Route: Oral, Intravenous, Subcutaneous, Topical, Intramuscular

3) By Indication: Breast Cancer, Glioblastoma, Lung Cancer, Colorectal Cancer, Ovarian Cancer, Sarcoma, Prostate Cancer, Other Indications

4) By End User: Cancer Research Institute, Cancer Hospitals

Subsegments:

1) By Chemotherapy Adjuvants: Alkylating Agents, Antimetabolites, Anthracyclines, Plant Alkaloids, Topoisomerase Inhibitors, Platinum-Based Compounds, Others

2) By Radiation Adjuvants: Radiosensitizers, Radioprotectors, Hypoxic Cell Sensitizers, Deoxyribonucleic Acid (DNA) Repair Inhibitors, Immune Modulating Agents Combined With Radiation

3) By Immunotherapy Adjuvants: Checkpoint Inhibitors, Cytokines, Cancer Vaccines, Adoptive Cell Transfer, Immune Modulating Agents

4) By Hormonal Adjuvants: Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Gonadotropin-Releasing Hormone Agonists Or Antagonists, Androgen Receptor Inhibitors, Estrogen Receptor Downregulators

5) By Targeted Therapy Adjuvants: Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, mTOR Inhibitors, v-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) Or Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitors, Vascular Endothelial Growth Factor (VEGF) Inhibitors

Which Ongoing Trends Are Expected To Shape The Oncology Adjuvants Market Outlook?

Major companies in the oncology adjuvants market are prioritizing the development of advanced solutions, such as immune checkpoint inhibitor adjuvant therapy, to improve the effectiveness of post-surgical treatments and increase overall patient survival by leveraging the body’s immune system against residual tumor cells. Immune checkpoint inhibitor adjuvant therapy involves drugs that block immune checkpoint proteins like PD-1, PD-L1, or CTLA-4, which normally suppress the immune system. For example, in January 2023, Merck & Co., Inc., a US-based pharmaceutical company, launched KEYTRUDA (pembrolizumab) as an adjuvant treatment after receiving approval from the Food and Drug Administration (FDA). This therapy is administered following surgical resection and platinum-based chemotherapy for patients diagnosed with Stage IB (T2a =4 centimeters), II, or IIIA non-small cell lung cancer (NSCLC). KEYTRUDA (pembrolizumab) achieves targeted immune checkpoint inhibition by blocking the PD-1 receptor, thereby restoring the immune system’s capacity to detect and attack cancer cells. It provides an effective adjuvant treatment alternative for non-small cell lung cancer (NSCLC) patients after surgery and chemotherapy, helping to lower the risk of cancer recurrence and enhance overall survival. Additionally, KEYTRUDA supports personalized cancer therapy by utilizing the patient’s immune response, making it an essential tool in modern immuno-oncology.

Who Are The Prominent Global Companies Shaping The Oncology Adjuvants Market?

Major companies operating in the oncology adjuvants market are Pfizer Inc., Johnson and Johnson, Roche Holding AG, Merck And Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, SEPPIC, Ipsen S.A., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Croda International Plc, Dynavax Technologies Corporation, Agenus Inc., Aurorium, Elicio Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/oncology-adjuvants-global-market-report

How Do Regional Market Performances Compare Within The Oncology Adjuvants Industry?

North America was the largest region in the oncology adjuvants market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology adjuvants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Oncology Adjuvants Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27370&type=smp

Browse Through More Reports Similar to the Global Oncology Adjuvants Market 2025, By The Business Research Company

Concrete Repair Mortars Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/concrete-repair-mortars-global-market-report

Cumene Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cumene-global-market-report

Supplementary Cementitious Materials Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/supplementary-cementitious-materials-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795